VERAXA Biotech Showcases BiTAC Platforms at BIO Convention

VERAXA Biotech (NASDAQ: VRXA) is spotlighting its innovative BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, scheduled for June 22–25 in San Diego. The company recently released new proof-of-concept data demonstrating the potential of its BiTAC-ADC platform to enhance cancer treatment precision through tumor-restricted activation, thereby minimizing off-target toxicity. This platform, combined with previously disclosed BiTAC-TCE data from the American Association for Cancer Research Annual Meeting in April 2026, underscores VERAXA's progress in developing differentiated therapies for multiple solid tumor indications.

VERAXA management plans to actively discuss partnering opportunities for both platforms at the BIO convention, highlighting the strategic value of these technologies. The company, founded on breakthroughs from the European Molecular Biology Laboratory (EMBL), focuses on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. By leveraging quality-by-design principles, VERAXA aims to accelerate its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.

For investors, the latest news and updates regarding VRXA are available in the company’s newsroom at http://ibn.fm/VRXA. This press release was distributed by MissionIR, a specialized communications platform under the Dynamic Brand Portfolio @ IBN, which provides syndicated content to enhance visibility for private and public companies. MissionIR offers services such as press release enhancement, editorial syndication to over 5,000 outlets, and social media distribution via IBN, helping clients reach investors, influencers, and the general public.